DK170637B1 - 1-phenyl-3-naphthalenyloxypropanaminer, fremgangsmåde til fremstilling af sådanne forbindelser og farmaceutiske præparater indeholdende disse - Google Patents

1-phenyl-3-naphthalenyloxypropanaminer, fremgangsmåde til fremstilling af sådanne forbindelser og farmaceutiske præparater indeholdende disse Download PDF

Info

Publication number
DK170637B1
DK170637B1 DK188288A DK188288A DK170637B1 DK 170637 B1 DK170637 B1 DK 170637B1 DK 188288 A DK188288 A DK 188288A DK 188288 A DK188288 A DK 188288A DK 170637 B1 DK170637 B1 DK 170637B1
Authority
DK
Denmark
Prior art keywords
compound
phenyl
naphthalenyloxy
formula
propanamine
Prior art date
Application number
DK188288A
Other languages
Danish (da)
English (en)
Other versions
DK188288D0 (da
DK188288A (da
Inventor
David Wayne Robertson
Dennis Charles Thomson
David Taiwai Wong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK188288D0 publication Critical patent/DK188288D0/da
Publication of DK188288A publication Critical patent/DK188288A/da
Application granted granted Critical
Publication of DK170637B1 publication Critical patent/DK170637B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK188288A 1987-04-09 1988-04-07 1-phenyl-3-naphthalenyloxypropanaminer, fremgangsmåde til fremstilling af sådanne forbindelser og farmaceutiske præparater indeholdende disse DK170637B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3653487A 1987-04-09 1987-04-09
US3653487 1987-04-09

Publications (3)

Publication Number Publication Date
DK188288D0 DK188288D0 (da) 1988-04-07
DK188288A DK188288A (da) 1989-01-12
DK170637B1 true DK170637B1 (da) 1995-11-20

Family

ID=21889125

Family Applications (1)

Application Number Title Priority Date Filing Date
DK188288A DK170637B1 (da) 1987-04-09 1988-04-07 1-phenyl-3-naphthalenyloxypropanaminer, fremgangsmåde til fremstilling af sådanne forbindelser og farmaceutiske præparater indeholdende disse

Country Status (23)

Country Link
EP (1) EP0288188B1 (es)
JP (1) JPH0637443B2 (es)
KR (1) KR960007723B1 (es)
CN (1) CN1020093C (es)
AT (1) ATE68473T1 (es)
AU (1) AU602971B2 (es)
CA (1) CA1329937C (es)
CY (1) CY1658A (es)
DE (1) DE3865504D1 (es)
DK (1) DK170637B1 (es)
EG (1) EG18584A (es)
ES (1) ES2045109T3 (es)
GR (1) GR3003267T3 (es)
HK (1) HK63992A (es)
HU (1) HU204767B (es)
IL (1) IL85988A (es)
MX (1) MX11031A (es)
NZ (1) NZ224161A (es)
PH (1) PH27141A (es)
PT (1) PT87163B (es)
SG (1) SG67092G (es)
SU (1) SU1568886A3 (es)
ZA (1) ZA882418B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
WO1993013049A1 (fr) * 1991-12-20 1993-07-08 Karin Elisabeth Peuschel Emploi de l'effet immunoactivant de 3-naphthyloxy-2-hydroxy-propylamines, interessant specialement pour l'immunite cellulaire, par exemple contre infections virales
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
DE69524962T4 (de) * 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
DE19956786A1 (de) * 1999-11-25 2001-05-31 Basf Ag Verfahren zur Herstellung optisch aktiver Amine
CN100402488C (zh) * 2006-03-15 2008-07-16 上海玛耀化学技术有限公司 一种达泊西汀的合成方法
WO2008035358A2 (en) * 2006-06-05 2008-03-27 Cadila Healthcare Limited Process for preparing dapoxetine
CN101367739B (zh) * 2008-09-24 2013-02-13 台州职业技术学院 N,n-二甲基-1-苯基-3-(1-萘氧基)丙胺制备工艺
DE102009015702A1 (de) 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
WO2011058572A2 (en) 2009-11-13 2011-05-19 Symed Labs Limited Solid dapoxetine
DE102009058321A1 (de) 2009-12-15 2011-06-16 Ratiopharm Gmbh Schmelztablette, enthaltend Dapoxetin
WO2011161690A1 (en) * 2010-06-23 2011-12-29 Symed Labs Limited Processes for the preparation of (+)-n,n-dimethyl-2-[1-(naphthalenyloxy) ethyl] benzene methanamine and intermediates thereof
CN102229538B (zh) * 2011-05-11 2013-11-13 中南大学 一种达泊西汀的合成方法
CN102850318A (zh) * 2011-07-01 2013-01-02 中国人民解放军军事医学科学院毒物药物研究所 新的选择性5-羟色胺重摄取抑制剂及其医药用途
CN103130660B (zh) * 2011-11-25 2014-09-17 厦门福满药业有限公司 一类达泊西汀的酸式盐及其晶体,以及晶体的制备方法
WO2013180675A1 (en) 2012-05-28 2013-12-05 Mahmut Bilgic Tablet formulation comprising dapoxetine
CN102746170A (zh) * 2012-07-28 2012-10-24 湖南尔文生物科技有限公司 一种达泊西汀的制备方法
US20150320677A1 (en) 2012-08-17 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2014027975A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
US20150231092A1 (en) 2012-08-17 2015-08-20 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
TR201309037A2 (tr) 2012-08-17 2014-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.
WO2014027979A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising tadalafil and dapoxetine
US20150202168A1 (en) 2012-08-17 2015-07-23 Sanovel llac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil
CN102942496B (zh) * 2012-11-28 2014-06-11 扬州工业职业技术学院 (s)-n,n-二甲基-3-(萘酚-1-氧基)-1-苯基丙基-1-胺的制备方法
EP2749553A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of enantiomerically pure S-(+)-N, N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine
CN106748825A (zh) * 2016-11-29 2017-05-31 聊城大学 一种达泊西汀的合成、拆分纯化和成盐方法
CN108853072A (zh) * 2018-08-03 2018-11-23 安徽省金楠医疗科技有限公司 一种盐酸达泊西汀片及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
NZ213651A (en) * 1984-10-11 1989-07-27 Hoffmann La Roche Tetrahydronapthalene derivatives and medicaments

Also Published As

Publication number Publication date
SU1568886A3 (ru) 1990-05-30
ZA882418B (en) 1989-12-27
HUT50316A (en) 1990-01-29
GR3003267T3 (en) 1993-02-17
HK63992A (en) 1992-08-28
IL85988A (en) 1992-08-18
KR880012526A (ko) 1988-11-28
IL85988A0 (en) 1988-09-30
PT87163B (pt) 1992-07-31
JPS63258837A (ja) 1988-10-26
EP0288188B1 (en) 1991-10-16
SG67092G (en) 1992-09-04
PH27141A (en) 1993-04-02
NZ224161A (en) 1990-04-26
AU1433588A (en) 1988-10-13
EP0288188A1 (en) 1988-10-26
DK188288D0 (da) 1988-04-07
CN1020093C (zh) 1993-03-17
HU204767B (en) 1992-02-28
JPH0637443B2 (ja) 1994-05-18
MX11031A (es) 1993-11-01
CN88102018A (zh) 1988-10-26
KR960007723B1 (ko) 1996-06-11
ATE68473T1 (de) 1991-11-15
CY1658A (en) 1993-05-14
EG18584A (en) 1994-07-30
CA1329937C (en) 1994-05-31
ES2045109T3 (es) 1994-01-16
PT87163A (pt) 1988-05-01
DE3865504D1 (de) 1991-11-21
DK188288A (da) 1989-01-12
AU602971B2 (en) 1990-11-01

Similar Documents

Publication Publication Date Title
DK170637B1 (da) 1-phenyl-3-naphthalenyloxypropanaminer, fremgangsmåde til fremstilling af sådanne forbindelser og farmaceutiske præparater indeholdende disse
AU2018342751B2 (en) Selective P2X3 modulators
US5135947A (en) 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
FI77018C (fi) Analogifoerfarande foer framstaellning av antidepressivt aktiv (-)-enantiomer av n-metyl-n-/3-(2-metylfenoxi) -3-fenylpropyl/amin och dess farmaceutiskt godtagbara salt.
WO2008035358A2 (en) Process for preparing dapoxetine
US20070299091A1 (en) Azaindole Carboxamides
EP0041488A1 (en) Therapeutically useful tetralin derivatives
AU622942B2 (en) Fluoxetine analog
US4996235A (en) 3,4-diphenylbutanamines
AU4991999A (en) Methods and compounds for treating depression and other disorders
PL136457B1 (en) Process for preparing novel derivatives of benzamide
US5457121A (en) Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
DK163182B (da) Dialkylaminoalkoxybenzylalkoholderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat og fremgangsmaade til fremstilling deraf
US4876282A (en) 1-Phenylalkylamines as selective serotonin uptake inhibitors
FR2735693A1 (fr) Nouvelles applications therapeutiques de n-cyclohexyl benzamides
JP2008513380A (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
NO874425L (no) Fremgangsmaate til fremstilling av (+)-1-isopropylamino-3-(o-pyrrol-l-yl)-fenoksy)-2-propanol og dets salter.
WO1999009001A1 (fr) Derives de phenylethanolaminotetraline et bronchodilatateurs
JPS62174041A (ja) エタノ−ルアミン誘導体

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed